Strategic Diagnostics to Take Q4 After-Tax Charge of up to $13M

The charges are related to impairment of goodwill and recordation of a valuation allowance against deferred tax assets. Strategic Dx also expects to report Q4 revenue growth of 2 percent.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.